Helicobacter pylori infection - Update for the clinician 2004;Helicobacter-pylori infektion - Ein update 2004

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 34-35, 2004, Pages 1821-1826

  Malfertheiner, P ^a   Peitz, U ^a   Wolle, K ^a   Treiber, G ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; RIFABUTIN; TETRACYCLINE; ANTIINFECTIVE AGENT; BACTERIUM ANTIBODY; PROTON PUMP;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DYSPEPSIA; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; INFECTION CONTROL; LABORATORY DIAGNOSIS; LABORATORY TEST; PATIENT COMPLIANCE; PREVALENCE; RETROSPECTIVE STUDY; REVIEW; TREATMENT INDICATION; ADOLESCENT; ADULT; BLOOD; CHILD; DISEASE TRANSMISSION; DRUG ANTAGONISM; HELICOBACTER INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTIC ULCER BLEEDING; PRESCHOOL CHILD; STOMACH TUMOR;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER HEMORRHAGE; PREVALENCE; PROTON PUMPS; STOMACH NEOPLASMS;

EID: 4444290122     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-831344     Document Type: Review

References (50)

1. Birkner B, Hotz J, Labenz J et al. Kurzgefasste Leitlinie zum Dyspepsie-Management. Dtsch Med Wochenschr 2004; 129(18): 1032-1034
2. Blaser MJ. Hypothesis: the changing relationship of H.p. and humans: implications for health and disease. J Infect Dis 1999; 179: 1523-1530
3. Brenner H, Arndt V, Stegmaier C et al. Is H.p. infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004; 159: 252-258
4. Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-973
5. Chan FK, To KF, Wu JC et al. Eradication of H.p. and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13
6. Chiba N, Veldhuyzen Van Zanten SJO, Escobedo S et al. Economic evaluation of H.p. eradication in the CADET-Hp randomized controlled trial of H.p. positive primary care patients with uninvestigated dyspepsia. Aliment Pharmacol Ther 2004; 19: 349-358
7. Chiba N, Veldhuyzen Van Zanten SJO, Sinclair P et al. Treating H.p. infection in primary care patients with uninvestigated dyspepsis: the Canadian adult dyspepsia empiric treatment - H.p. positive (CADET-Hp) randomised controlled trial. Brit Med J 2002; 324: 1-7
8. Churin Y, Al-Ghoul L, Kepp O et al. Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response. J Cell Biol 2003; 28 (161): 249-255
9. Dore MP, Osato MS, Malaty HM et al. Characterization of a culture method to recover Helicobacter pylori from the feces of infected patients. Helicobacter 2000; 5: 165-168
10. El Omar EM, Rabkin CS, Gammon MD et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-201
11. Fischbach W, Goebeler-Kolve ME, Dragosics B et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004; 53: 34-37
12. Gisbert J, Calvet X, Bujanda L et al. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003; 8: 90-94
13. Glupczynski Y, Megraud F, Lopez-Brea M et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-823
14. Glynn MK, Friedman CR, Gold BD et al. Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors. Clin Infect Dis 2002; 35: 1059-1065
15. Granquist A, Bredberg A, Sveger T et al. A longitudinal cohort study on the prevalence of Helicobacter pylori antibodies in Swedish children and adolescents. Acta Paediatr 2002; 91: 636-640
16. Grimm W, Fischbach W. Helicobacter pylori infection in children and juveniles: an epidemiological study on prevalence, socio-economic factors and symptoms. Dtsch Med Wochenschr 2003; 128: 1878-1883
17. Heuberger F, Pantoflickowa D, Gassner M et al. H.p. infection in Swiss adolescents. Prevalence and risk factors. Eur J Gastroenterol Hepatol 2003; 15: 179-183
18. Huang J, Hunt R. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole. Aliment Pharmacol Ther 1999; 13: 857-64
19. Kist M, Glocker E. Helicobacter pylori Infektionen: ResiNet - eine bundesweite Sentinelstudie zur Resistenzentwicklung. Epidemiol Bull 2003; 47: 389-391
20. Klotz U, Schwab M, Treiber G. CYP2C19 Polymorphism and Proton Pump Inhibitors. Basic Clin Pharmacol Toxicol 2004; 95: 2-8
21. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 12-20
22. Labenz J, Blum AL, Bolten WW et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in H.p. positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002; 51: 329-335
23. Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-2038
24. Leodolter A, Dominguez-Munoz JE, Von Arnim U et al. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999; 94: 2100-2104
25. Leodolter A, Malfertheiner P. Aktuelle diagnostische Methoden zum Nachweis der Helicobacter-pylori-Infektion. Dtsch Med Wochenschr 2001; 126: 207-209
26. Leodolter A, Wolle K, Malfertheiner P. Current standards in the diagnosis of H. pylori infection. Dig Dis 2001; 19: 116-122
27. Leodolter A, Peitz U, Ebert MP et al. Comparison of two enzyme immunoassays for the assessment of Helicobacter pylori status in stool specimens after eradication therapy. Am J Gastroenterol 2002; 97: 1682-1686
28. Leodolter A, Vaira D, Bazzoli F et al. European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test. Aliment Pharmacol Ther 2003; 18: 927-931
29. Leodolter A, Wolle K, Peitz U et al. Evaluation of a near-patient fecal antigen test for the assessment of Helicobacter pylori status. Diagn Microbiol Infect Dis 2004; 48: 145-147
30. Malfertheiner P. H.p. eradication does not exacerbate gastro-oesophageal reflux disease. Gut 2004; 53: 312-313
31. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180
32. Malfertheiner P, Mössner J, Fischbach W et al. H.p. eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 2003; 15: 615-625
33. Malfertheiner P, Peitz U, Treiber G. What constitutes failure for Helicobacter pylori eradication therapy? Can J Gastroenterol 2003; 17 (Suppl B): 53B-57B
34. Manes G, Menchise A, De Nucci C et al. Empirical prescribing for dyspepsia, randomised controlled trial of test and treat versus omeprazole treatment. Brit Med J 2003; 326: 1118
35. Mc Coll KEL, Murray LS, Gillen D et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H.p. testing alone in the management for dyspepsia. Brit Med J 2002; 324: 999-1002
36. Meining AG, Bayerdorffer E, Stolte M. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients. Eur J Gastroenterol Hepatol 1999; 11: 717-720
37. Melo ET, Lopes EP, Almeida JR, Albuquerque HF, Moura IM. Seroprevalence of H. pylori antibodies in medical students and residents in Recife, Brazil. Clin Gastroenterol 2003; 36: 134-8
38. Mitchell HM, Hu P, Chi Y et al. A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation. Gastroenterology 1998; 114: 256-261
39. Nardone G, Morgner A. Helicobacter pylori and gastric malignancies. Helicobacter 2003; 8,1: 44-52
40. Osato MS, Reddy R, Graham DY. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 1999; 12: 341-347
41. Peitz U, Leodolter A, Wex T et al. Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding. Z Gastroenterol 2004; 42: 141-146
42. Raymond J, Kalach N, Bergeret M et al. Prevalence of Helicobacter pylori infection in children according to their age. A retrospective study. Arch Pediatr 1998; 5: 617-620
43. Roma-Giannikou E, Karameris A, Balatsos B et al. Intrafamilial spread of Helicobacter pylori: a genetic analysis. Helicobacter 2003; 8: 15-20
44. Rothenbacher D, Brenner H. Burden of H.p. and H.p.-related diseases in developed countries: recent developments and future implications. Microbes Infect 2003; 5 (8): 693-703
45. Schilling D, Demel A, Adamek HE et al. A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study. Dig Liver Dis 2003; 35: 217-221
46. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86
47. Triantafillidis JK, Gikas A, Hyphantis T et al. Helicobacter pylori infection in hospital workers over a 5-year period. Correlation with demographic and clinical parameters. J Gastroenterol 2002; 37: 1005-1013
48. Uemura N, Okamoto S, Yamamoto S et al. H.p. infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789
49. Wolle K, Leodolter A, Malfertheiner P et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51: 705-9
50. Wong BCY, Lam SK, Wong WM et al. H.p. eradication to prevent gastric cancer in a high-risk region of China. J Amer Med Assoc 2004; 291 (2): 187-194